Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Average PT from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been given a consensus recommendation of "Buy" by the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $26.60.

Several analysts have issued reports on ATXS shares. Wedbush reaffirmed an "outperform" rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. JMP Securities started coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an "outperform" rating and a $26.00 price target on the stock. Finally, Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP grew its stake in shares of Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company's stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Fcpm Iii Services B.V. acquired a new position in shares of Astria Therapeutics in the fourth quarter valued at about $25,680,000. Vanguard Group Inc. grew its stake in shares of Astria Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company's stock valued at $23,936,000 after acquiring an additional 41,833 shares in the last quarter. Northern Trust Corp grew its stake in shares of Astria Therapeutics by 4.5% in the fourth quarter. Northern Trust Corp now owns 458,234 shares of the biotechnology company's stock valued at $4,097,000 after acquiring an additional 19,893 shares in the last quarter. Finally, Redmile Group LLC grew its stake in shares of Astria Therapeutics by 11.4% in the fourth quarter. Redmile Group LLC now owns 346,278 shares of the biotechnology company's stock valued at $3,096,000 after acquiring an additional 35,394 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Down 4.1 %

Shares of ATXS stock traded down $0.21 during trading on Wednesday, reaching $4.96. The company's stock had a trading volume of 363,792 shares, compared to its average volume of 374,682. The business has a fifty day moving average price of $5.52 and a 200-day moving average price of $8.03. The company has a market cap of $279.91 million, a price-to-earnings ratio of -2.37 and a beta of 0.68. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01. Research analysts anticipate that Astria Therapeutics will post -1.65 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.